Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy

Tommaso Schirinzi, Giulia Maria Sancesario, Giulia Di Lazzaro, Simona Scalise, Vito Luigi Colona, Paola Imbriani, Nicola Biagio Mercuri, Sergio Bernardini, Anthony E. Lang, Antonio Pisani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Progressive Supranuclear Palsy (PSP) is a four-repeat tauopathy with high phenotypic and neuropathological variability, highlighting the urgent need for effective disease biomarkers. Quantitative analysis of cerebrospinal fluid (CSF) proteins reflecting pathological changes of CNS is currently used as biomarkers of multiple neurodegenerative disorders for both early differential diagnosis and prognostic clustering of patients. In this study, we thus assessed the clinical usefulness of a panel of CSF biomarker in PSP patients presenting with Richardson’s Syndrome. CSF levels of 42-beta-amyloid, total-tau, phosphorylated-tau, and both 42-beta-amyloid/phosphorylated-tau and phosphorylated-tau/total-tau ratios were comparatively evaluated in 39 PSP patients, 31 patients with Parkinson’s Disease (PD) and 58 gender-/age-matched healthy controls. Specific gold-standard clinical scores were obtained. Diagnostic accuracy and clinical correlates of each biomarker were measured with receiver operating curve analysis and Spearman’s test/linear regression, respectively. In PSP, 42-beta-amyloid was lower than either controls or PD; total-tau and phosphorylated-tau were instead reduced compared to controls, but similar to PD. At the cut-off value of 623 pg/ml, 42-beta-amyloid significantly distinguished PSP from controls and PD. Likewise, phosphorylated-tau/total-tau ratio also supported differential diagnosis between PSP and PD (cut-off = 0.185). 42-beta-amyloid was inversely associated with PSP severity, as measured with PSP Rating Scale. Our study demonstrates that CSF 42-beta-amyloid is reduced in PSP patients, proportionally to clinical severity, thus suggesting a potential use as disease biomarker. Moreover, phosphorylated-tau/total-tau ratio resulted helpful in the early differential diagnosis between PSP and PD.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalJournal of Neural Transmission
DOIs
Publication statusAccepted/In press - Jun 14 2018

Fingerprint

Progressive Supranuclear Palsy
tau Proteins
Amyloid beta-Peptides
Cerebrospinal Fluid
Amyloid
Parkinson Disease
Biomarkers
Differential Diagnosis
Early Diagnosis
Tauopathies
Cerebrospinal Fluid Proteins
Gold
Neurodegenerative Diseases
Cluster Analysis
Linear Models

Keywords

  • Amyloid-beta
  • CSF biomarkers
  • Parkinson’s Disease
  • Progressive Supranuclear Palsy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. / Schirinzi, Tommaso; Sancesario, Giulia Maria; Di Lazzaro, Giulia; Scalise, Simona; Colona, Vito Luigi; Imbriani, Paola; Mercuri, Nicola Biagio; Bernardini, Sergio; Lang, Anthony E.; Pisani, Antonio.

In: Journal of Neural Transmission, 14.06.2018, p. 1-7.

Research output: Contribution to journalArticle

Schirinzi, Tommaso ; Sancesario, Giulia Maria ; Di Lazzaro, Giulia ; Scalise, Simona ; Colona, Vito Luigi ; Imbriani, Paola ; Mercuri, Nicola Biagio ; Bernardini, Sergio ; Lang, Anthony E. ; Pisani, Antonio. / Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. In: Journal of Neural Transmission. 2018 ; pp. 1-7.
@article{89add5fbae7b4858b9f1464529ab311b,
title = "Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy",
abstract = "Progressive Supranuclear Palsy (PSP) is a four-repeat tauopathy with high phenotypic and neuropathological variability, highlighting the urgent need for effective disease biomarkers. Quantitative analysis of cerebrospinal fluid (CSF) proteins reflecting pathological changes of CNS is currently used as biomarkers of multiple neurodegenerative disorders for both early differential diagnosis and prognostic clustering of patients. In this study, we thus assessed the clinical usefulness of a panel of CSF biomarker in PSP patients presenting with Richardson’s Syndrome. CSF levels of 42-beta-amyloid, total-tau, phosphorylated-tau, and both 42-beta-amyloid/phosphorylated-tau and phosphorylated-tau/total-tau ratios were comparatively evaluated in 39 PSP patients, 31 patients with Parkinson’s Disease (PD) and 58 gender-/age-matched healthy controls. Specific gold-standard clinical scores were obtained. Diagnostic accuracy and clinical correlates of each biomarker were measured with receiver operating curve analysis and Spearman’s test/linear regression, respectively. In PSP, 42-beta-amyloid was lower than either controls or PD; total-tau and phosphorylated-tau were instead reduced compared to controls, but similar to PD. At the cut-off value of 623 pg/ml, 42-beta-amyloid significantly distinguished PSP from controls and PD. Likewise, phosphorylated-tau/total-tau ratio also supported differential diagnosis between PSP and PD (cut-off = 0.185). 42-beta-amyloid was inversely associated with PSP severity, as measured with PSP Rating Scale. Our study demonstrates that CSF 42-beta-amyloid is reduced in PSP patients, proportionally to clinical severity, thus suggesting a potential use as disease biomarker. Moreover, phosphorylated-tau/total-tau ratio resulted helpful in the early differential diagnosis between PSP and PD.",
keywords = "Amyloid-beta, CSF biomarkers, Parkinson’s Disease, Progressive Supranuclear Palsy",
author = "Tommaso Schirinzi and Sancesario, {Giulia Maria} and {Di Lazzaro}, Giulia and Simona Scalise and Colona, {Vito Luigi} and Paola Imbriani and Mercuri, {Nicola Biagio} and Sergio Bernardini and Lang, {Anthony E.} and Antonio Pisani",
year = "2018",
month = "6",
day = "14",
doi = "10.1007/s00702-018-1893-1",
language = "English",
pages = "1--7",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer-Verlag Wien",

}

TY - JOUR

T1 - Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy

AU - Schirinzi, Tommaso

AU - Sancesario, Giulia Maria

AU - Di Lazzaro, Giulia

AU - Scalise, Simona

AU - Colona, Vito Luigi

AU - Imbriani, Paola

AU - Mercuri, Nicola Biagio

AU - Bernardini, Sergio

AU - Lang, Anthony E.

AU - Pisani, Antonio

PY - 2018/6/14

Y1 - 2018/6/14

N2 - Progressive Supranuclear Palsy (PSP) is a four-repeat tauopathy with high phenotypic and neuropathological variability, highlighting the urgent need for effective disease biomarkers. Quantitative analysis of cerebrospinal fluid (CSF) proteins reflecting pathological changes of CNS is currently used as biomarkers of multiple neurodegenerative disorders for both early differential diagnosis and prognostic clustering of patients. In this study, we thus assessed the clinical usefulness of a panel of CSF biomarker in PSP patients presenting with Richardson’s Syndrome. CSF levels of 42-beta-amyloid, total-tau, phosphorylated-tau, and both 42-beta-amyloid/phosphorylated-tau and phosphorylated-tau/total-tau ratios were comparatively evaluated in 39 PSP patients, 31 patients with Parkinson’s Disease (PD) and 58 gender-/age-matched healthy controls. Specific gold-standard clinical scores were obtained. Diagnostic accuracy and clinical correlates of each biomarker were measured with receiver operating curve analysis and Spearman’s test/linear regression, respectively. In PSP, 42-beta-amyloid was lower than either controls or PD; total-tau and phosphorylated-tau were instead reduced compared to controls, but similar to PD. At the cut-off value of 623 pg/ml, 42-beta-amyloid significantly distinguished PSP from controls and PD. Likewise, phosphorylated-tau/total-tau ratio also supported differential diagnosis between PSP and PD (cut-off = 0.185). 42-beta-amyloid was inversely associated with PSP severity, as measured with PSP Rating Scale. Our study demonstrates that CSF 42-beta-amyloid is reduced in PSP patients, proportionally to clinical severity, thus suggesting a potential use as disease biomarker. Moreover, phosphorylated-tau/total-tau ratio resulted helpful in the early differential diagnosis between PSP and PD.

AB - Progressive Supranuclear Palsy (PSP) is a four-repeat tauopathy with high phenotypic and neuropathological variability, highlighting the urgent need for effective disease biomarkers. Quantitative analysis of cerebrospinal fluid (CSF) proteins reflecting pathological changes of CNS is currently used as biomarkers of multiple neurodegenerative disorders for both early differential diagnosis and prognostic clustering of patients. In this study, we thus assessed the clinical usefulness of a panel of CSF biomarker in PSP patients presenting with Richardson’s Syndrome. CSF levels of 42-beta-amyloid, total-tau, phosphorylated-tau, and both 42-beta-amyloid/phosphorylated-tau and phosphorylated-tau/total-tau ratios were comparatively evaluated in 39 PSP patients, 31 patients with Parkinson’s Disease (PD) and 58 gender-/age-matched healthy controls. Specific gold-standard clinical scores were obtained. Diagnostic accuracy and clinical correlates of each biomarker were measured with receiver operating curve analysis and Spearman’s test/linear regression, respectively. In PSP, 42-beta-amyloid was lower than either controls or PD; total-tau and phosphorylated-tau were instead reduced compared to controls, but similar to PD. At the cut-off value of 623 pg/ml, 42-beta-amyloid significantly distinguished PSP from controls and PD. Likewise, phosphorylated-tau/total-tau ratio also supported differential diagnosis between PSP and PD (cut-off = 0.185). 42-beta-amyloid was inversely associated with PSP severity, as measured with PSP Rating Scale. Our study demonstrates that CSF 42-beta-amyloid is reduced in PSP patients, proportionally to clinical severity, thus suggesting a potential use as disease biomarker. Moreover, phosphorylated-tau/total-tau ratio resulted helpful in the early differential diagnosis between PSP and PD.

KW - Amyloid-beta

KW - CSF biomarkers

KW - Parkinson’s Disease

KW - Progressive Supranuclear Palsy

UR - http://www.scopus.com/inward/record.url?scp=85048540984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048540984&partnerID=8YFLogxK

U2 - 10.1007/s00702-018-1893-1

DO - 10.1007/s00702-018-1893-1

M3 - Article

SP - 1

EP - 7

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

ER -